Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8933 USD | +10.82% | +21.87% | +10.28% |
Apr. 25 | Transcript : HOOKIPA Pharma Inc. - Special Call | |
Apr. 25 | HOOKIPA Pharma Inc. Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab | CI |
Financials (USD)
Sales 2024 * | 30.79M | Sales 2025 * | 11.82M | Capitalization | 88.39M |
---|---|---|---|---|---|
Net income 2024 * | -63M | Net income 2025 * | -84M | EV / Sales 2024 * | 2.87 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 7.48 x |
P/E ratio 2024 * |
-1.93
x | P/E ratio 2025 * |
-1.81
x | Employees | 165 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 78.46% |
Latest transcript on HOOKIPA Pharma Inc.
1 day | +10.82% | ||
1 week | +21.87% | ||
Current month | +25.46% | ||
1 month | +24.24% | ||
3 months | +27.47% | ||
6 months | +103.49% | ||
Current year | +10.28% |
Managers | Title | Age | Since |
---|---|---|---|
Jörn Aldag
CEO | Chief Executive Officer | 65 | 16-05-31 |
Reinhard Kandera
DFI | Director of Finance/CFO | 54 | 17-03-31 |
Klaus Orlinger
CTO | Chief Tech/Sci/R&D Officer | 46 | 12-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jörn Aldag
CEO | Chief Executive Officer | 65 | 16-05-31 |
Chairman | 63 | 17-09-30 | |
Reinhard Kandera
DFI | Director of Finance/CFO | 54 | 17-03-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 0.8933 | +10.82% | 2,899,851 |
24-04-25 | 0.8061 | -5.16% | 1,859,973 |
24-04-24 | 0.85 | +11.11% | 10,443,832 |
24-04-23 | 0.765 | +8.20% | 791,938 |
24-04-22 | 0.707 | -3.55% | 872,297 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.28% | 88.39M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- HOOK Stock